Welcome to our dedicated page for IQVIA HOLDINGS SEC filings (Ticker: IQV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IQVIA Holdings Inc. filings document a NYSE-listed operating company with common stock under the IQV symbol and a business centered on clinical research services, commercial insights and healthcare intelligence. Form 8-K reports document quarterly and annual operating results, segment disclosures for R&D Solutions and Commercial Solutions, share repurchase authorizations and amendments to the company's credit agreement.
Proxy and governance filings describe annual meeting matters, director elections and appointments, executive compensation, equity incentive plans and stockholder voting items. The filings also provide formal records of capital-structure terms, material agreements and board oversight for IQVIA's life sciences and healthcare services business.
IQVIA Holdings Inc. has a planned sale of 558 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on the NYSE, targeted for 07/29/2026. The shares are valued at $136,827.18, tied to earlier restricted stock and performance share awards granted by the issuer on multiple dates from 2022 through 2026.
IQVIA Holdings Inc. reported Q2 2026 revenues of $4,368 million, up 8.7% year over year, with income from operations flat at $506 million. Net income attributable to IQVIA was $256 million and diluted EPS was $1.53. For the first half, revenues reached $8,519 million and diluted EPS was $3.14.
Commercial Solutions grew Q2 revenue 8.6% to $1,793 million and segment profit 10.6% to $419 million, while Research & Development Solutions grew revenue 8.8% to $2,575 million and profit 11.2% to $526 million. Contracted R&D backlog was $34.2 billion, with $9.2 billion expected to convert within 12 months, and remaining performance obligations totaled $36.4 billion.
Operating cash flow for the first half was $1,176 million. Cash and cash equivalents were $1,909 million against principal debt of $16,081 million. The company repurchased 5.5 million shares for $950 million and increased its total repurchase authorization to $15,725 million, with $2,819 million remaining.
IQVIA Holdings reported strong second‑quarter 2026 results, with revenue of $4,368 million, up 8.7% year-over-year, and segment revenue of $1,793 million in Commercial Solutions and $2,575 million in Research & Development Solutions. R&DS delivered record net new bookings of $3.15 billion, a 19% increase and a 1.22x book‑to‑bill ratio, supporting a contracted backlog of $34.2 billion.
GAAP net income was $256 million, or $1.53 diluted EPS. Adjusted EBITDA reached $994 million, up 9.2%, and Adjusted Diluted EPS was $3.15, up 12.1% year-over-year. Operating cash flow rose to $558 million and Free Cash Flow to $360 million. The company repurchased $398 million of stock in the quarter, with $2,819 million authorization remaining and a net leverage ratio of 3.59x.
On the back of this performance, IQVIA raised its full‑year 2026 guidance, now expecting revenue between $17,275 million and $17,475 million, Adjusted EBITDA between $4,000 million and $4,050 million, and Adjusted Diluted EPS between $12.80 and $13.00, reflecting a higher 6.5% revenue growth midpoint versus 5.8% previously.
IQVIA Holdings Inc. director Wims Morris Leslie received a grant of 148 deferred shares on July 14, 2026 at a reference value of $207.83 per share. Each deferred share converts into one share of common stock upon settlement under the Non-Employee Director Deferral Plan, increasing his deferred-share holdings to 6,784. Settlement generally occurs when he ceases to be a director, upon a change in control, or upon death, and the deferred shares have no expiry date.
IQVIA Holdings Inc. reported that director Colleen A. Goggins received a grant of 183 deferred shares on July 14, 2026. Each deferred share converts into one share of common stock upon settlement when she ceases to be a director, upon a change in control, or upon death. There is no expiry date, and she now holds 5,297 deferred shares directly.
Fasano Jim reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director Jim Fasano received a grant of 195 deferred shares on July 14, 2026, at $207.83 per share. Each deferred share is convertible into one share of common stock upon settlement under the Non-Employee Director Deferral Plan, when he ceases to be a director, upon a change in control, or upon death, and there is no expiry date. Following this award, Fasano holds 6,268 deferred shares directly.
DANHAKL JOHN G reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director John G. Danhakl received a grant of 160 deferred shares on 2026-07-14, representing rights to an equal number of common shares upon settlement. Under the Non-Employee Director Deferral Plan, these units settle when he leaves the board, upon a change in control, or upon death. Following the award, he holds 3,289 deferred shares directly.
IQVIA Holdings Inc. reported that its wholly owned subsidiary IQVIA Inc. issued €950,000,000 of 4.625% senior notes due 2033. These unsecured notes provide long-term euro-denominated funding. Interest is payable semi-annually on June 15 and December 15, beginning December 15, 2026.
The notes mature on June 15, 2033, unless earlier repurchased or redeemed under their terms. IQVIA plans to use the net proceeds to refinance certain existing indebtedness and to pay related fees and expenses, effectively replacing older debt with this new issue.
The notes were issued under an Indenture dated June 11, 2026, among IQVIA Inc. as issuer, U.S. Bank Trust Company, National Association as trustee, and certain subsidiaries as guarantors. The issuer may redeem the notes before maturity, including a make-whole premium before June 15, 2029, and thereafter at a redemption premium that declines from 2.313% to 0%.